Weisel K, Berger S, Thorn K, et al. - In this multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study, researchers assessed the safety, pharmacokinetics (PK), and preliminary effectiveness of GSK2982772, a RIPK1 inhibitor, in moderate to severe rheumatoid arthritis (RA). Participants in the study were patients with moderate to severe RA who had received ≥12 weeks’ stable-dose conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy. Study participants were randomized (2:1) to GSK2982772 60 mg or placebo orally 2 or 3 times daily for 84 days. In total, 52 patients were randomized (placebo, 18; GSK2982772, 34). Findings suggested that administration of GSK2982772 60 mg BID or TID for 84 days in patients with moderate to severe RA was safe and well-tolerated. However, inhibiting RIPK1 activity with GSK2982772 did not result in differences in efficacy or joint damage when compared to placebo.